Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost
Brachytherapy · 2025
DOI: 10.1016/j.brachy.2024.07.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2025. Verfasst von Johan Staby Olsén und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, General Hospital of Karlstad, Karlstad, Sweden; Department of oncology, Faculty of Medicine and Health, Örebro University, Ör…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Radiation Dose Hypofractionation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Treating localized high-risk prostate cancer with a combination of external beam radiation therapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) is a common approach. Moderately hypofractionated EBRT and a single HDR-BT boost simplifies the treatment. We aim to present our five-year results. METHODS: In this study, 355 patients treated with moderately hypofractionated EBRT (42 Gy in 14 fractions) and a single HDR-BT boost (14.5 Gy) at Örebro University Hospital between 2008 and 2018 were included. They were followed with regular PSA tests. RESULTS: The median age of the cohort was 70 years (range: 51-81) and the median follow-up duration was 56 months (range: 6-150). Among them, 45% were classified as very high-risk, 38% as high-risk and 17% as intermediate-risk. Adjuvant androgen deprivation therapy (ADT) with a median duration of 24 months was given to 75% of the patient cohort. The estimated 5-year failure free survival rates were 79% (whole cohort), 66% (very high-risk), 90% (high-risk) and 85% (intermediate-risk), respectively. Initial PSA > 10 ng/mL, Gleason score 9-10 and tumor stage T3 were significantly associated with biochemical failure (BF). A PSA bounce occurred in 53 (15%) cases and was inversely associated with BF (p = 0.001) for patients receiving ADT. CONCLUSIONS: Moderately hypofractionated EBRT and a single HDR-BT boost seems to be an effective treatment against intermediate- and high-risk localized prostate cancer. Treatment escalation strategies should be investigated for very high-risk patients where the risk of recurrence remains high.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, General Hospital of Karlstad, Karlstad, Sweden; Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Electronic address: johan.stabyolsen@regionvarmland.se.
- Department of Oncology, Örebro University Hospital, Örebro, Sweden; Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Medical Physics, Örebro University Hospital, Örebro, Sweden.
Zitieren
APA
Staby Olsén, J., Valachis, A., PhLic, L. K., & Johansson, B. (2025). Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.07.005
Vancouver
Staby Olsén J, Valachis A, PhLic LK, Johansson B. Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost. Brachytherapy. 2025. doi:10.1016/j.brachy.2024.07.005
BibTeX
@article{StabyOlsn2025,
author = {Staby Olsén, Johan and Valachis, Antonios and PhLic, Leif Karlsson and Johansson, Bengt},
title = {Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost},
journal = {Brachytherapy},
year = {2025},
doi = {10.1016/j.brachy.2024.07.005}
}
EUVIMED